Clinical trials: Operable Breast Neoplasms
Breast Cancer
Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six…
- Trial name
- esozao (NCT01654367)
- Testing
- Zoledronic Acid and Aromatase Inhibitors
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University
Breast Cancer
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00524459
- Testing
- docetaxel, pegylated liposomal doxorubicin hydrochloride, conventional surgery
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)
Pre-operative chemotherapy in operable breast cancer, phase III study comparing a short intensive pre-operative chemotherapy with the same therapy initiated shortly after surgery (peri-operatively) (POCOB) (EORTC 10902)
- Trial name
- NCT00544505
- Testing
- Fluorouracil/Epirubicin/Cyclophosphamide
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer, Molecular Pathway Deregulation
Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC
- Conditions
- Breast Cancer, Molecular Pathway Deregulation, Treatment
- Trial name
- BrCa (NCT06830590)
- Testing
- Molecular characterisation
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Breast Neoplasms
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
- Trial name
- NCT00174343
- Testing
- exemestane (Aromasin®)
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- Pfizer
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as neoadjuvant chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2…
- Trial name
- NCT01648608
- Testing
- Exemestane
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Tianjin Medical University
Breast Cancer
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
Post operative adjuvant chemotherapy followed by adjuvant Tamoxifen vs nil for patients with operable breast cancer
- Trial name
- NCT00538330
- Testing
- Tamoxifen
- Volunteers
- 2,000 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002579
- Testing
- CMF regimen, cyclophosphamide, fluorouracil
- Where
- 10 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Scottish Cancer Therapy Network
Breast Cancer
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given…
- Trial name
- NCT00002707
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 145 sites in United States, Canada
- Volunteers
- 2,411 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer
Select 60 cases of women with breast cancer at clinical stage of T1-4N0-2M0. Then treat them with 4 cycles of TAC (Abraxane 260mg/m2,EPI 60 mg/m2 ,CTX 500 mg/m2, 21day/cycle) as neoadjuvant chemotherapy.
- Trial name
- NCT01647672
- Testing
- Abraxane
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University
Breast Cancer
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002581
- Testing
- cyclophosphamide, fluorouracil, methotrexate
- Where
- 9 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Scottish Cancer Therapy Network
Breast Cancer
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases.
- Trial name
- NCT00010153
- Testing
- fulvestrant, conventional surgery
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer.
- Trial name
- NCT00038402
- Testing
- Herceptin, Taxol, Fluorouracil
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
Primary Objectives: Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer.
- Trial name
- NCT00050167
- Testing
- Paclitaxel, Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 603 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Currently patients with breast cancer are treated with one of several very similar combinations of drugs.
- Trial name
- NCT00017095
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 39 sites in Belgium, France and 7 more
- Volunteers
- 1,856 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002460
- Testing
- goserelin acetate, tamoxifen citrate, ablative endocrine surgery
- Where
- 34 sites in Belgium, United Kingdom
- Sponsor
- Cancer Research UK
Breast Cancer
Evaluating New Surgical Technique in Management of Female Patients With Operable Multifocal Breast Cancer
Multi-focal Breast Cancers(MFBC) still have undiscoverable Clinical Significance reflecting on a debatable surgical decision for this Category of breast cancer.
- Trial name
- NCT03900299
- Testing
- oncoplastic breast surgery
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Alexandria University
Breast Cancer
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole or fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes or by blocking the use of estrogen by the…
- Trial name
- NIMFEA (NCT00629616)
- Testing
- anastrozole, fulvestrant
- Where
- 6 sites in France
- Volunteers
- 116 people
- Sponsor
- UNICANCER